addictions and the brain
DESCRIPTION
Dr. Daniel Boone, Medical Director of La Hacienda Treatment Center, discusses the correlation between addictions and our brains.TRANSCRIPT
![Page 1: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/1.jpg)
Addictions and the Brain
![Page 2: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/2.jpg)
Acknowledgements
• La Hacienda Treatment Center
• American Society of Addiction Medicine
• National Institute of Drug Abuse
![Page 3: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/3.jpg)
Definition
• A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability.
![Page 4: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/4.jpg)
DSM IV Criteria for dependency: At least 3 of the 7 below
1. Withdrawal2. Tolerance3. The substance is taken in larger amounts or over a longer period
than was intended.4. There is a persistent desire or unsuccessful efforts to cut down or
control substance use.5. A great deal of time is spent in activities necessary to obtain the
substance, use the substance, or recover from its effects.6. Important social, occupational, or recreational activities are given
up or reduced because of the substance use.7. The substance use is continued despite knowledge of having a
persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance.
![Page 5: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/5.jpg)
Dispute between behavior and disease
![Page 6: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/6.jpg)
Present understanding of the Hypothalamus location of the
disease hypothesis.
![Page 7: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/7.jpg)
![Page 8: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/8.jpg)
![Page 9: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/9.jpg)
![Page 10: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/10.jpg)
![Page 11: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/11.jpg)
![Page 12: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/12.jpg)
Dispute regarding behavior versus disease
![Page 13: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/13.jpg)
![Page 14: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/14.jpg)
![Page 15: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/15.jpg)
![Page 16: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/16.jpg)
![Page 17: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/17.jpg)
00
5050
100100
150150
200200
00 6060 120120 180180
Time (min)Time (min)
% o
f B
asal
DA
Ou
tpu
t%
of
Bas
al D
A O
utp
ut
NAc shellNAc shell
EmptyEmpty
BoxBox FeedingFeeding
Source: Di Chiara et al.Source: Di Chiara et al.
FOODFOOD
100100
150150
200200
DA
Co
nce
ntr
ati
on
(%
Bas
elin
e)D
A C
on
cen
tra
tio
n (
% B
asel
ine)
MountsMountsIntromissionsIntromissionsEjaculationsEjaculations
1515
00
55
1010
Co
pu
latio
n F
req
ue
nc
yC
op
ula
tion
Fre
qu
en
cy
SampleNumberSampleNumber
11 22 33 44 55 66 77 88 99 1010 1111 1212 1313 1414 1515 1616 1717
ScrScrScrScrBasBasFemale 1 PresentFemale 1 Present
ScrScrFemale 2 PresentFemale 2 Present
ScrScr
Source: Fiorino and PhillipsSource: Fiorino and Phillips
SEXSEX
Natural Rewards Elevate Dopamine Natural Rewards Elevate Dopamine LevelsLevels
Natural Rewards Elevate Dopamine Natural Rewards Elevate Dopamine LevelsLevels
![Page 18: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/18.jpg)
00100100200200300300400400500500600600700700800800900900
1000100011001100
00 11 22 33 44 5 hr5 hr
Time After AmphetamineTime After Amphetamine
% o
f B
as
al
Re
lea
se
% o
f B
as
al
Re
lea
se
DADADOPACDOPACHVAHVA
AccumbensAccumbens AMPHETAMINEAMPHETAMINE
00
100100
200200
300300
400400
00 11 22 33 44 5 hr5 hrTime After CocaineTime After Cocaine
% o
f B
as
al
Re
lea
se
% o
f B
as
al
Re
lea
se
DADADOPACDOPACHVAHVA
AccumbensAccumbensCOCAINECOCAINE
00
100100
150150
200200
250250
00 11 22 33 44 5hr5hrTime After MorphineTime After Morphine
% o
f B
as
al
Re
lea
se
% o
f B
as
al
Re
lea
se
AccumbensAccumbens
0.50.51.01.02.52.51010
Dose (mg/kg)Dose (mg/kg)
MORPHINEMORPHINE
00
100100
150150
200200
250250
00 11 22 3 hr3 hrTime After NicotineTime After Nicotine
% o
f B
as
al
Re
lea
se
% o
f B
as
al
Re
lea
se
AccumbensAccumbensCaudateCaudate
NICOTINENICOTINE
Source: Di Chiara and ImperatoSource: Di Chiara and Imperato
Effects of Drugs on Dopamine LevelsEffects of Drugs on Dopamine LevelsEffects of Drugs on Dopamine LevelsEffects of Drugs on Dopamine Levels
![Page 19: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/19.jpg)
Post-Chronic Amphetamine (10 days)
Pre-Amphetamine/Control
Striatal FDOPA Activity
4 weeks
6 months
1 year
2 years
Superior Inferior
![Page 20: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/20.jpg)
![Page 21: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/21.jpg)
![Page 22: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/22.jpg)
Dopamine Transporters in Methamphetamine AbusersDopamine Transporters in Methamphetamine Abusers
Methamphetamine abusers have significant reductions in dopamine Methamphetamine abusers have significant reductions in dopamine transporters.transporters.
Normal ControlNormal Control
Methamphetamine AbuserMethamphetamine Abuser p < 0.0002p < 0.0002
Do
pam
ine
Tra
nsp
ort
ers
(Bm
ax/
Kd
)
NormalControls
MethAbusers
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
BNL - UCLA - SUNYBNL - UCLA - SUNYNIDA - ONDCP - DOENIDA - ONDCP - DOE
![Page 23: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/23.jpg)
Dopamine Transporters in Methamphetamine AbusersDopamine Transporters in Methamphetamine Abusers
BNL/UCLA/SUNYBNL/UCLA/SUNY
NIDA, ONDCP, DOENIDA, ONDCP, DOE
Motor TaskMotor TaskLoss of dopamine transporters Loss of dopamine transporters in the meth abusers may result in the meth abusers may result in slowing of motor reactions.in slowing of motor reactions.
Memory TaskMemory TaskLoss of dopamine transporters Loss of dopamine transporters in the meth abusers may result in the meth abusers may result in memory impairment.in memory impairment.
7 8 9 10 11 12 131.0
1.2
1.4
1.6
1.8
2.0
Time Gait(seconds)
468101214161.01.2
1.4
1.6
1.8
2.0
Delayed Recall(words remembered)
Do
pam
ine
Tra
nsp
ort
erB
max
/Kd
![Page 24: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/24.jpg)
CocaineCocaine
FoodFood
DA
D2
Rec
epto
r A
vai l
abil
ity
MethMeth
AlcoholAlcohol
Dopamine D2 Receptors in Addiction
Experimentalgroups
Controlgroups
![Page 25: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/25.jpg)
![Page 26: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/26.jpg)
![Page 27: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/27.jpg)
![Page 28: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/28.jpg)
![Page 29: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/29.jpg)
![Page 30: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/30.jpg)
![Page 31: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/31.jpg)
![Page 32: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/32.jpg)
![Page 33: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/33.jpg)
Drug Use Addiction TreatmentNormal
Challenge:
![Page 34: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/34.jpg)
![Page 35: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/35.jpg)
![Page 36: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/36.jpg)
Three Major Relapse Pathways
I. Cross Addicting DrugsII. People/Place/ThingsIII. B.H.A.L.T.
![Page 37: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/37.jpg)
Cross Addicting Drugs
a. Chemical of choice
b. Related drugs
c. Tobacco
d. Life long relapse pathway
![Page 38: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/38.jpg)
People/Place/Things
a. History of discovery
b. Three month limit for relapse
![Page 39: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/39.jpg)
B.H.A.L.T.
a. Boredom
b. Hunger
c. Anger/emotions
d. Loneliness
e. Tiredness
![Page 40: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/40.jpg)
Relapse Prevention Medications
I. Antabuse
II. Campral
III. ReVia
IV. Vivitrol
V. Off label
![Page 41: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/41.jpg)
Antabuse
a. Mechanism of action
b. Dosing
c. Side Effects
d. Efficacy
![Page 42: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/42.jpg)
Campral
a. Mechanism of action
b. Dosing
c. Side Effects
d. Efficacy
![Page 43: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/43.jpg)
ReVia
a. Mechanism of action
b. Dosing
c. Side Effects
d. Efficacy
![Page 44: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/44.jpg)
Vivitrol
a. Mechanism of action
b. Dosing
c. Side Effects
d. Efficacy
![Page 45: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/45.jpg)
Off label
![Page 46: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/46.jpg)
Phase 3 Clinical TrialsOn A Number of Promising Drugs
Phase 3 Clinical TrialsOn A Number of Promising Drugs
Cabergoline
Disulfiram (Antabuse)
Reserpine
Selegiline
Cabergoline
Disulfiram (Antabuse)
Reserpine
Selegiline
CocaineCocaine MethamphetamineMethamphetamine
BupropionBupropion LofexidineLofexidine
OpiatesOpiates
![Page 47: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/47.jpg)
Cocaine Medication Development ProjectsCocaine Medication Development Projects
Phase II ScreenPhase II Screen Phase IIIPhase III
DisulfiramSelegiline TSDisulfiramSelegiline TS
Phase IPhase I Phase IIPhase II
ButorphanolDAS 431GBR 12909MetyraponeModafinilNS 2359Tolcapone
ButorphanolDAS 431GBR 12909MetyraponeModafinilNS 2359Tolcapone
BP 4897Cocaine VaccineDextromethorphanIsradipineLamotrigineMemantineOndansetronSibutramine
BP 4897Cocaine VaccineDextromethorphanIsradipineLamotrigineMemantineOndansetronSibutramine
AmantadineAmlodipineBaclofenBupropionButorphanolCabergolineCaptoprilClopidogrelDisulfiramGabapentinMemantineMethylphenidateNaltrexoneOxazepamPemolinePropranololReserpineRisperidoneSertralineTaurineTiagabineVenlafaxine
AmantadineAmlodipineBaclofenBupropionButorphanolCabergolineCaptoprilClopidogrelDisulfiramGabapentinMemantineMethylphenidateNaltrexoneOxazepamPemolinePropranololReserpineRisperidoneSertralineTaurineTiagabineVenlafaxine
Opiate Medication Development ProjectsOpiate Medication Development Projects
Phase IPhase I
CycloserineCycloserineDepot NaltrexoneDepot NaltrexoneEnadolineEnadolineLamotrigineLamotrigineTramadolTramadol
Phase IIPhase II Phase IIIPhase III
BuprenorphineBuprenorphine
Buprenorphine/NaloxoneLofexidineBuprenorphine/NaloxoneLofexidine
BupropionBuspironeClonidineLofexidineMemantineMethylphenidateMidazolam/N20NaloxoneNaltrexoneNefazedone
BupropionBuspironeClonidineLofexidineMemantineMethylphenidateMidazolam/N20NaloxoneNaltrexoneNefazedone
Methamphetamine Addiction Pharmacotherapiesin Clinical Trials
Methamphetamine Addiction Pharmacotherapiesin Clinical Trials
AmlodipineBaclofenDesipramineFluoxetineFlupenthixolGabapentinIsradipineOlanzapineOndansetronPemolineSelegilineVenlafaxine
AmlodipineBaclofenDesipramineFluoxetineFlupenthixolGabapentinIsradipineOlanzapineOndansetronPemolineSelegilineVenlafaxine
Phase IPhase I Phase IIPhase II
BupropionDisulfiramLobelineReserpineSelegiline
BupropionDisulfiramLobelineReserpineSelegiline
![Page 48: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/48.jpg)
Dual Diagnosis
1. Prevalence
2. Testing
3. Treatment
![Page 49: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/49.jpg)
![Page 50: Addictions and the Brain](https://reader036.vdocuments.mx/reader036/viewer/2022081519/5589252ed8b42ade2f8b4591/html5/thumbnails/50.jpg)
Spiritual Component of Recovery